WO1997043278A1 - Somatostatin agonists and antagonists - Google Patents

Somatostatin agonists and antagonists Download PDF

Info

Publication number
WO1997043278A1
WO1997043278A1 PCT/DK1997/000222 DK9700222W WO9743278A1 WO 1997043278 A1 WO1997043278 A1 WO 1997043278A1 DK 9700222 W DK9700222 W DK 9700222W WO 9743278 A1 WO9743278 A1 WO 9743278A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
propyl
thiourea
imidazol
pyridin
Prior art date
Application number
PCT/DK1997/000222
Other languages
English (en)
French (fr)
Inventor
Michael Ankersen
Carsten Enggaard Stidsen
Henrik Sune Andersen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP54040897A priority Critical patent/JP2001525793A/ja
Priority to EP97921646A priority patent/EP0912551A1/de
Priority to AU27647/97A priority patent/AU2764797A/en
Publication of WO1997043278A1 publication Critical patent/WO1997043278A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
PCT/DK1997/000222 1996-05-14 1997-05-14 Somatostatin agonists and antagonists WO1997043278A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP54040897A JP2001525793A (ja) 1996-05-14 1997-05-14 ソマトスタチンの作動因子及び拮抗因子
EP97921646A EP0912551A1 (de) 1996-05-14 1997-05-14 Somatostatin-agonisten und -antagonisten
AU27647/97A AU2764797A (en) 1996-05-14 1997-05-14 Somatostatin agonists and antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK57696 1996-05-14
DK0576/96 1996-05-14

Publications (1)

Publication Number Publication Date
WO1997043278A1 true WO1997043278A1 (en) 1997-11-20

Family

ID=8095123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1997/000222 WO1997043278A1 (en) 1996-05-14 1997-05-14 Somatostatin agonists and antagonists

Country Status (5)

Country Link
EP (1) EP0912551A1 (de)
JP (1) JP2001525793A (de)
AU (1) AU2764797A (de)
WO (1) WO1997043278A1 (de)
ZA (1) ZA974147B (de)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058646A1 (en) * 1997-06-24 1998-12-30 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
WO1999064401A2 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Imidazolyl derivatives and their use as somatostatin receptor ligands
EP0977751A1 (de) * 1997-04-04 2000-02-09 Merck & Co., Inc. Somatostatin-agonisten
WO2000012111A2 (en) * 1998-09-01 2000-03-09 The University Of British Columbia Selective treatment of endothelial somatostatin receptors
EP0984779A1 (de) * 1997-04-04 2000-03-15 Merck & Co., Inc. Somatostatin agonisten
EP1023061A1 (de) * 1997-04-04 2000-08-02 Merck & Co., Inc. Somatostatinagoniste
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy
US6127343A (en) * 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6159941A (en) * 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
FR2796945A1 (fr) * 1999-07-30 2001-02-02 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
EP1123918A1 (de) * 1998-10-20 2001-08-16 Takeda Chemical Industries, Ltd. Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten
EP1159964A2 (de) 2000-05-31 2001-12-05 Pfizer Products Inc. Zusammenstellungen und Methoden zur Förderung der Beweglichkeit des Verdauungstrakts
US6387932B1 (en) 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
WO2004004726A1 (en) * 2002-07-08 2004-01-15 Astrazeneca Ab Mchir antagonists
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
WO2005075436A3 (en) * 2004-02-05 2005-12-08 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2007098716A1 (es) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Compuestos analogos a los secretagogos peptidicos de la hormona de crecimiento y preparaciones que los contienen
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US7462599B2 (en) 2003-10-15 2008-12-09 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US7473761B2 (en) 2000-08-01 2009-01-06 Novartis Ag Somatostatin analogues
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
EP2117540A1 (de) * 2007-03-01 2009-11-18 Probiodrug AG Neue verwendung von glutaminyl-cyclase-hemmern
US7741362B2 (en) 2003-10-06 2010-06-22 Siegfried Wurster Somatostatin receptor 1 and/or 4 selective agonists and antagonists
EA013790B1 (ru) * 2004-02-05 2010-06-30 Пробиодруг Аг Новые ингибиторы глутаминилциклазы
EP2457925A1 (de) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Verfahren zur Herstellung eines makrozyklischen Modulators des Ghrelin-Rezeptors und Zwischenprodukte
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
EP2644618A1 (de) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. Intermediaten für die Synthese von Makrozyklische Ghrelin-Rezeptormodulatoren
WO2015037716A1 (ja) 2013-09-12 2015-03-19 住友化学株式会社 含窒素飽和複素環化合物
WO2021065985A1 (ja) 2019-09-30 2021-04-08 株式会社理研バイオ－アルツハイマー病の発症前診断と予防的治療のために ソマトスタチン受容体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1590338B1 (de) * 2002-12-04 2009-08-26 Ore Pharmaceuticals Inc. Melanocortin-rezeptormodulatoren

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007891A1 (en) * 1986-06-19 1987-12-30 Cedona Pharmaceuticals B.V. N-(2-substituted alkyl)-n'-[(imidazole-4-yl)alkyl]guanidine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5021431A (en) * 1985-04-02 1991-06-04 Heumann Pharma Gmbh & Co. Imidazolyl alkyl guanidine derivatives, processes for their preparation and pharmaceutical preparations containing these compounds
EP0448765A1 (de) * 1990-03-30 1991-10-02 HEUMANN PHARMA GMBH & CO Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021431A (en) * 1985-04-02 1991-06-04 Heumann Pharma Gmbh & Co. Imidazolyl alkyl guanidine derivatives, processes for their preparation and pharmaceutical preparations containing these compounds
WO1987007891A1 (en) * 1986-06-19 1987-12-30 Cedona Pharmaceuticals B.V. N-(2-substituted alkyl)-n'-[(imidazole-4-yl)alkyl]guanidine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0448765A1 (de) * 1990-03-30 1991-10-02 HEUMANN PHARMA GMBH & CO Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) * 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6159941A (en) * 1996-05-14 2000-12-12 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
EP0977751A4 (de) * 1997-04-04 2000-04-26 Merck & Co Inc Somatostatin-agonisten
EP0977751A1 (de) * 1997-04-04 2000-02-09 Merck & Co., Inc. Somatostatin-agonisten
EP0984779A1 (de) * 1997-04-04 2000-03-15 Merck & Co., Inc. Somatostatin agonisten
EP1023061A4 (de) * 1997-04-04 2001-04-11 Merck & Co Inc Somatostatinagoniste
EP0984779A4 (de) * 1997-04-04 2000-05-10 Merck & Co Inc Somatostatin agonisten
EP1023061A1 (de) * 1997-04-04 2000-08-02 Merck & Co., Inc. Somatostatinagoniste
WO1998058646A1 (en) * 1997-06-24 1998-12-30 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US6124256A (en) * 1998-03-27 2000-09-26 Haeyry; Pekka Method for the prevention of a patient's fibroproliferative vasculopathy
US6852725B1 (en) 1998-06-12 2005-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S. A. S. Imidazolyl derivatives
WO1999064401A2 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Imidazolyl derivatives and their use as somatostatin receptor ligands
US7238695B2 (en) 1998-06-12 2007-07-03 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Imidazolyl derivatives
WO1999064401A3 (en) * 1998-06-12 2003-04-17 Sod Conseils Rech Applic Imidazolyl derivatives and their use as somatostatin receptor ligands
JP2003523921A (ja) * 1998-06-12 2003-08-12 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス イミダゾリル誘導体
AU746963B2 (en) * 1998-06-12 2002-05-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazolyl derivatives
WO2000012111A3 (en) * 1998-09-01 2000-05-25 Univ British Columbia Selective treatment of endothelial somatostatin receptors
WO2000012111A2 (en) * 1998-09-01 2000-03-09 The University Of British Columbia Selective treatment of endothelial somatostatin receptors
EP1123918A1 (de) * 1998-10-20 2001-08-16 Takeda Chemical Industries, Ltd. Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten
EP1123918A4 (de) * 1998-10-20 2002-08-07 Takeda Chemical Industries Ltd Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten
US7160887B1 (en) 1998-10-20 2007-01-09 Takeda Pharmaceutical Company Limited Aromatic amine derivatives, their production and use
US6387932B1 (en) 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
US6759415B1 (en) 1999-07-30 2004-07-06 Societe De Conseils De Recherches Et D' Applications Scientifiques Hydantoin thiohydantoin pyrimidinedione and thioxopyrimidinone derivatives preparation method and use as medicines
WO2001009090A2 (fr) * 1999-07-30 2001-02-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinoneses, leurs procedes de preparation et leur application a titre de medicaments
JP2003518011A (ja) * 1999-07-30 2003-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） ヒダントイン類、チオヒダントイン類、ピリミジンジオン類及びチオキソピリミジノン類の新規誘導体、その製造方法並びにその医薬としての使用
WO2001009090A3 (fr) * 1999-07-30 2002-08-08 Sod Conseils Rech Applic Derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinoneses, leurs procedes de preparation et leur application a titre de medicaments
FR2796945A1 (fr) * 1999-07-30 2001-02-02 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
KR100712587B1 (ko) * 1999-07-30 2007-05-02 소시에떼 드 꽁세이으 드 르세르세 에 따블리까시옹 시앙띠피끄 (에스.세.에르.아.에스.) 신규 히단토인, 티오히단토인, 피리미딘디온 및티옥소피리미디논의 유도체, 그의 제조 방법 및의약으로서의 용도
EP1159964A2 (de) 2000-05-31 2001-12-05 Pfizer Products Inc. Zusammenstellungen und Methoden zur Förderung der Beweglichkeit des Verdauungstrakts
US7939625B2 (en) 2000-08-01 2011-05-10 Novartis Ag Somatostatin analogues
US7566734B2 (en) 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
US9035021B2 (en) 2000-08-01 2015-05-19 Novartis Ag Somatostatin analogues
US8822637B2 (en) 2000-08-01 2014-09-02 Novartis Ag Somatostatin analogues
US7638546B1 (en) 2000-08-01 2009-12-29 Ipsen Pharma S.A.S. Imidazolyl derivatives
US7473761B2 (en) 2000-08-01 2009-01-06 Novartis Ag Somatostatin analogues
WO2004004726A1 (en) * 2002-07-08 2004-01-15 Astrazeneca Ab Mchir antagonists
US8338120B2 (en) 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US7741362B2 (en) 2003-10-06 2010-06-22 Siegfried Wurster Somatostatin receptor 1 and/or 4 selective agonists and antagonists
US7462599B2 (en) 2003-10-15 2008-12-09 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
WO2005075436A3 (en) * 2004-02-05 2005-12-08 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EA013790B1 (ru) * 2004-02-05 2010-06-30 Пробиодруг Аг Новые ингибиторы глутаминилциклазы
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2005082845A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Novel therapies with somatostatin receptor agonists
WO2005082844A1 (en) * 2004-02-27 2005-09-09 Oy Juvantia Pharma Ltd Treatment of diseases by using a somatostatin receptor agonist
EP2457893A1 (de) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Zwischenprodukte für makrozyklische Modulatoren des Ghrelin-Rezeptors
EP2457925A1 (de) 2004-06-18 2012-05-30 Tranzyme Pharma, Inc. Verfahren zur Herstellung eines makrozyklischen Modulators des Ghrelin-Rezeptors und Zwischenprodukte
WO2007098716A1 (es) 2006-02-28 2007-09-07 Centro De Ingeniería Genética Y Biotecnología Compuestos analogos a los secretagogos peptidicos de la hormona de crecimiento y preparaciones que los contienen
EP2644618A1 (de) 2007-02-09 2013-10-02 Tranzyme Pharma, Inc. Intermediaten für die Synthese von Makrozyklische Ghrelin-Rezeptormodulatoren
EP2481408A3 (de) * 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
EP2117540A1 (de) * 2007-03-01 2009-11-18 Probiodrug AG Neue verwendung von glutaminyl-cyclase-hemmern
WO2015037716A1 (ja) 2013-09-12 2015-03-19 住友化学株式会社 含窒素飽和複素環化合物
WO2021065985A1 (ja) 2019-09-30 2021-04-08 株式会社理研バイオ－アルツハイマー病の発症前診断と予防的治療のために ソマトスタチン受容体

Also Published As

Publication number Publication date
AU2764797A (en) 1997-12-05
JP2001525793A (ja) 2001-12-11
EP0912551A1 (de) 1999-05-06
ZA974147B (en) 1997-11-14

Similar Documents

Publication Publication Date Title
WO1997043278A1 (en) Somatostatin agonists and antagonists
US6083960A (en) Constrained somatostatin agonists and antagonists
US6127343A (en) Somatostatin agonists and antagonists
EP1056725B1 (de) Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
US7329670B1 (en) Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
KR20190017931A (ko) Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
JP2001518895A (ja) ソマトスタチン作働薬
TW201722920A (zh) 新穎愛帕琳（ａｐｅｌｉｎ）受體促效劑及使用方法
KR20050038631A (ko) 글리코겐 신타제 키나제 3의 피롤 기제 억제제
JP2019532072A (ja) ３−スルホニル−５−アミノピリジン−２，４−ジオール ａｐｊアゴニスト
NZ229239A (en) Substituted diperazine derivatives and pharmaceutical compositions
TW200412957A (en) Therapeutic agents
EP1019050B1 (de) Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten
EP0912556B1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
US6762186B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6159941A (en) Use of somatostatin agonists and antagonists for treating diseases related to the eye
JPS60105672A (ja) 胃抗分泌剤としてのチアトリアジンジオキサイド類
US6518287B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6528522B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
CN100448869C (zh) 用于治疗糖尿病的苯胺基吡唑衍生物
EP0059903A1 (de) Diaminooxadiazole, ihre Verwendung zur Verminderung der Magensekretion und Verfahren zu ihrer Herstellung
UA76233C2 (en) N-substituted pyrrolidine derivatives as dipeptidylpeptidase iv inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997921646

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997921646

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997921646

Country of ref document: EP